HC Wainwright & Co. Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $4
Author: Benzinga Newsdesk | July 14, 2025 06:32am
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $4.